ACORN CAPITAL MICRO OPPORTUNITIES FUND

INVESTMENT UPDATE
November 2024



Top 5 Stocks

Company	Sector
Aroa Biosurgery	Health Care
Meeka Metals	Resources
SRG Global	Industrials
Superloop	Telco
Vysarn	Industrials
Weight Top 5	17.9%

Sector Exposures



Fund Overview

APIR Code	ACQ4764AU
Benchmark	S&P ASX Emerging Companies Accumulation Index
Distributions	Annual
Management Fee	1.20%
Incentive Fee	20% above benchmark
Highwater mark	Yes
Responsible Entity	Evolution Trustees Ltd
Pricing frequency	Daily
Min. investment	\$20,000

Ratings*

Lonsec "Recommended"



Contact: Phil Morgan Phone: 0421 915 040

philmorgan@acorncapital.com.au

Commentary 1

The S&P/ASX Emerging Companies Index returned -0.9% in November, underperforming the S&P ASX Small Ordinaries Index (+1.3%) and the ASX100 (+3.8%). It is notable that the one year forward PE discount between ASX Small Caps and the S&P ASX100 is now approaching one standard deviation, highlighting a potential valuation advantage for the smaller end of the market cap spectrum. Within the S&P/ASX Emerging Companies Index, Industrials (ex-Capital Goods) rose 12.3%—aided by a takeover offer for Close the Loop—while the IT sector rose 11.3% driven by Catapult's +40.5% return following strong first half FY25 results. The Resources sector lagged, falling 8.8% over the month, with its large index weighting of 27%, also one of the main reasons the overall index return was negative for the month

The portfolio returned -3.3% in November, driven by underperformance in the Energy, Healthcare and Consumer Discretionary sectors. Peninsular Energy fell 47% to be the main stock drag on performance, while Amplia Therapeutics (down 34.8% as it digests its recent capital raise), City Chic (down 27.5% after a soft trading update) and Environmental Group (down 27.3% after a disappointing downgrade to FY25 EBITDA due to what management believe is an isolated, one-off cost overrun from a single project) all contributed to the underperformance. Despite this, it was pleasing to see strong performance from Aroa (up 14.8% on positive first half results and guidance) and SRG Global (up 18.2% after announcing \$700m of contracts with key repeat clients) both of which are Top 5 holding in the fund.

Performance

	1 mth %	3 mth %	6 mth %	FYTD %	1 year %	3 year %p.a.	Since incept. %p.a
Micro Opportunities Fund ²	-3.38	4.65	9.16	10.35	25.57	-3.77	12.08
Benchmark	-0.88	6.51	4.79	8.85	22.28	-2.56	15.37
Alpha	-2.50	-1.86	+4.37	+1.50	+3.29	-1.21	-3.29

Attribution

Contributors			
Company		Impact %	
Aroa Biosurgery	Health Care	0.62	
EML Payments	Financials	0.56	
SRG Global	Industrials	0.56	

Detra	etors	
Peninsula Energy	Energy	-1.31
Environmental Group	Industrials	-0.53
Andean Silver	Resources	-0.48

^{1.} Commentary for month of November 2024 2. Net performance is based on redemption price for the period, after all fees and costs. Assumes all distributions are reinvested.

This report is published by Acorn Capital Limited ("Acorn") ABN: 51 082 694 531, AFSL: 227605 and is general information only and is not intended as an offer or solicitation with respect to the purchase or sale of any securities by Acorn or the responsible entity and Issuer. Evolution Trustees Limited ("Evolution") ABN: 29 611 839 519 AFSL: 486217 is the responsible entity and Issuer of the Acorn Capital Micro Opportunities Fund (the Fund) ARSN: 673 344 833. Acorn is the investment or fund manager of the Fund. This report does not take into account the investment objectives, financial situation or needs of any particular person. Investors should obtain personal financial advice based on their own particular needs and circumstances before making any investment decision. Any person considering investing, holding or disposing of units in the Fund should review the Product Disclosure Statement for the Fund dated 15 December 2023, Reference Guide, Target Market Determination and any other material published by Acorn. This information is available at www.acorncapital.com.au. Evolution and Acorn do not guarantee repayment of capital or any particular rate of return from the Fund. Past performance is no guarantee of future performance. Investment returns have been calculated in accordance with normal industry practice utilising movements in unit price and assuming reinvestment of all distributions of income and realised profits. The information is current at the date of publication, and whilst all care has been taken in its preparation, neither Acorn nor Evolution gives any representation or warranty as to the reliability, completeness or accuracy of the information contained in this report. Statements in this report have been obtained from and are based upon sources that Acorn believes to be reliable, however Acorn does not guarantee their accuracy, and any such information may be incomplete or condensed. All opinions and estimates included in this report are subject to change without notice. Not to be reproduced with

*The rating issued 10/2024 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved







